Phase 1Not yet recruiting

The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin

Sponsor
Johns Hopkins University (Academic or other)
Enrollment
80 planned
Conditions
Psilocybin Intoxication
Interventions
0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 15mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 25mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink; 0mg Psilocybin Capsule + 0.08% BAC Alcoholic Drink
Ages
adults, older adults
Registry
NCT07877987

Full record on ClinicalTrials.gov

From the registry

This study will evaluate the subjective and behavioral effects of psilocybin relative to placebo and alcohol.

Primary outcomes

  • Driving performance as assessed by standard deviation of lateral position (SDLP)
  • Driving performance as assessed by global drive score during the simulated driving task
  • Total Clues and Cues exhibited during Standardized Field Sobriety Tests (SFSTs)
  • Drug Effect Questionnaire (DEQ) - Feel Drug Effect

History

  1. Primary completion expected

  2. Expected to start

  3. Registered